# Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

> **NCT02546791** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 101 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT02546791
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-22
- **Primary completion:** 2016-11-30
- **Final completion:** 2017-03-29
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546791, "Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02546791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*